

Charts revised April 2015. Further information available at www.hep-druginteractions.org**Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.**BOC, Boceprevir; DCV, Daclatasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; TVR, Telaprevir; Peg IFN, Pegylated Interferon; RBV, Ribavirin.
Cells have been left blank for the unassessed interactions with PEG-IFN or RBV.

	BOC	DCV	LED/SOF	OBV/PTV/r	OBV/PTV/r + DSV	SMV	SOF	TVR	Peg IFN α	RBV
Calcium Channel Blockers										
Amlodipine	■	■	■	■	■	■	■	■	■	■
Diltiazem	■	■	■	■	■	■	■	■	■	■
Felodipine	■	■	■	■	■	■	■	■	■	■
Nicardipine	■	■	■	■	■	■	■	■	■	■
Nifedipine	■	■	■	■	■	■	■	■	■	■
Nisoldipine	■	■	■	■	■	■	■	■	■	■
Nitrendipine	■	■	■	■	■	■	■	■	■	■
Verapamil	■	■	■	■	■	■	■	■	■	■
Contraceptives and Hormonal Replacements										
Drospirenone	●	■	■	■	■	■	■	■	■	■
Ethinylestradiol	■	■	■	●	●	■	■	■	■	■
Norethisterone (norethindrone)	■	■	■	■	■	■	■	■	■	■
Cytotoxics										
Dasatinib	●	■	■	■	■	■	■	■	■	■
Doxorubicin	■	■	■	■	■	■	■	■	■	■
Everolimus	■	■	■	■	■	■	■	■	■	■
Imatinib	●	■	■	■	■	■	■	●	■	■
Irinotecan	■	■	■	■	■	■	■	■	■	■
Methotrexate	■	■	■	■	■	■	■	■	■	■
Rituximab	■	■	■	■	■	■	■	■	■	■
Sorafenib	■	■	■	■	■	■	■	■	■	■
Sunitinib	■	■	■	●	●	■	■	●	■	■
Tamoxifen	■	■	■	■	■	■	■	■	■	■
Vinblastine	■	■	■	■	■	■	■	■	■	■
Vincristine	■	■	■	■	■	■	■	■	■	■
Erectile Dysfunction Agents										
Sildenafil	■	■	■	■	■	■	■	■	■	■
Tadalafil	■	■	■	■	■	■	■	■	■	■
Vardenafil	■	■	■	■	■	■	■	■	■	■
Gastrointestinal Agents										
Aluminium hydroxide	■	■	■	■	■	■	■	■	■	■
Alverine citrate	■	■	■	■	■	■	■	■	■	■
Antacids	■	■	■	■	■	■	■	■	■	■
Aprepitant	■	■	■	■	■	■	■	■	■	■
Bisacodyl	■	■	■	■	■	■	■	■	■	■
Cimetidine	■	■	■	■	■	■	■	■	■	■
Cisapride	●	■	■	●	●	■	■	●	■	■
Domperidone	■	■	■	■	■	■	■	■	■	■
Droperidol	■	■	■	■	■	■	■	■	■	■
Esomeprazole	■	■	■	■	■	■	■	■	■	■
Famotidine	■	■	■	■	■	■	■	■	■	■
Lactulose	■	■	■	■	■	■	■	■	■	■
Lansoprazole	■	■	■	■	■	■	■	■	■	■
Loperamide	■	■	■	■	■	■	■	■	■	■
Mebevine	■	■	■	■	■	■	■	■	■	■
Mesalazine	■	■	■	■	■	■	■	■	■	■
Metoclopramide	■	■	■	■	■	■	■	■	■	■
Omeprazole	■	■	■	■	■	■	■	■	■	■
Ondansetron	■	■	■	■	■	■	■	■	■	■
Pantoprazole	■	■	■	■	■	■	■	■	■	■
Pralanopride	■	■	■	■	■	■	■	■	■	■
Rabeprazole	■	■	■	■	■	■	■	■	■	■
Ranitidine	■	■	■	■	■	■	■	■	■	■
Senna	■	■	■	■	■	■	■	■	■	■
Trimebutine	■	■	■	■	■	■	■	■	■	■

	BOC	DCV	LED/SOF	OBV/PTV/r	OBV/PTV/r + DSV	SMV	SOF	TVR	Peg IFN α	RBV
Hepatitis Drugs										
Adefovir	■	■	■	■	■	■	■	■	■	■
Boceprevir	■	■	■	■	■	■	■	■	■	■
Daclatasvir	■	■	■	■	■	■	■	■	■	■
Entecavir	■	■	■	■	■	■	■	■	■	■
Lamivudine	■	■	■	■	■	■	■	■	■	■
Ledipasvir/Sofosbuvir	■	■	■	■	■	■	■	■	■	■
OBV/PTV/r ± DSV	■	■	■	■	■	■	■	■	■	■
Peg Interferon alfa	■	■	■	■	■	■	■	■	■	■
Ribavirin	■	■	■	■	■	■	■	■	■	■
Simeprevir	■	■	■	■	■	■	■	■	■	■
Sofosbuvir	■	■	■	■	■	■	■	■	■	■
Telaprevir	■	■	■	■	■	■	■	■	■	■
Telbivudine	■	■	■	■	■	■	■	■	■	■
Tenofovir	■	■	■	■	■	■	■	■	■	■
Herbals/Supplements/Vitamins										
Ascorbic acid (Vitamin C)	■	■	■	■	■	■	■	■	■	■
Folic acid	■	■	■	■	■	■	■	■	■	■
Garlic	■	■	■	■	■	■	■	■	■	■
Ginkgo biloba	■	■	■	■	■	■	■	■	■	■
Ginseng	■	■	■	■	■	■	■	■	■	■
Grapefruit juice	■	■	■	■	■	■	■	■	■	■
Iron supplements	■	■	■	■	■	■	■	■	■	■
Milk thistle	■	■	■	■	■	■	■	■	■	■
Retinol (Vitamin A)	■	■	■	■	■	■	■	■	■	■
Riboflavin (Vitamin B2)	■	■	■	■	■	■	■	■	■	■
Serenoa repens	■	■	■	■	■	■	■	■	■	■
St John's wort	●	●	●	●	●	●	●	●	●	●
Thiamine (Vitamin B1)	■	■	■	■	■	■	■	■	■	■
Valerian	■	■	■	■	■	■	■	■	■	■
Vitamin E	■	■	■	■	■	■	■	■	■	■
HIV Drugs										
<i>Entry/Integrase Inhibitors</i>										
Dolutegravir	■	■	■	■	■	■	■	■	■	■
Elvitegravir/cobicistat	■	■	■	■	■	■	■	■	■	■
Maraviroc	■	■	■	■	■	■	■	■	■	■
Raltegravir	■	■	■	■	■	■	■	■	■	■
<i>NNRTIs</i>										
Delavirdine	■	■	■	■	■	■	■	■	■	■
Efavirenz	■	■	■	■	■	■	■	■	■	■
Etravirine	■	■	■	■	■	■	■	■	■	■
Nevirapine	■	■	■	■	■	■	■	■	■	■
Rilpivirine	■	■	■	■	■	■	■	■	■	■
<i>NRTIs</i>										
Abacavir	■	■	■	■	■	■	■	■	■	■
Didanosine	■	■	■	■	■	■	■	■	■	■
Emtricitabine	■	■	■	■	■	■	■	■	■	■
Lamivudine	■	■	■	■	■	■	■	■	■	■
Stavudine	■	■	■	■	■	■	■	■	■	■
Tenofovir	■	■	■	■	■	■	■	■	■	■
Zidovudine	■	■	■	■	■	■	■	■	■	■
<i>PIs</i>										
Atazanavir	■	■	■	■	■	■	■	■	■	■
Darunavir	■	■	■	■	■	■	■	■	■	■
Fosamprenavir	■	■	■	■	■	■	■	■	■	■
Indinavir	■	■	■	■	■	■	■	■	■	■
Lopinavir	■	■	■	■	■	■	■	■	■	■
Nelfinavir	■	■	■	■	■	■	■	■	■	■
Ritonavir	■	■	■	■	■	■	■	■	■	■
Saquinavir	■	■	■	■	■	■	■	■	■	■
Tipranavir	■	■	■	■	■	■	■	■	■	■

Key to symbolsFilled symbols indicate further information is available at www.hep-druginteractions.org.

Empty symbols indicate the interaction has not been assessed (either by study or within the product label) and has been predicted based on the metabolic profiles of the drugs.

●/○	These drugs should not be coadministered
■/□	Potential interaction – may require close monitoring, alteration of drug dosage or timing of administration
◆/◇	No clinically significant interaction expected

Notes

- Predicted interactions are based on known metabolic pathways. Interaction studies performed with boceprevir and telaprevir have shown some inconsistencies which suggest unknown mechanisms may contribute to drug-drug interactions and therefore predictions may not always reflect the clinical situation.
- Caution is required in patients with hepatic impairment as this may also increase drug levels.
- Where advice differs between countries, the charts reflect the more cautious option.
- Further comedications will be added when information is available.

© Liverpool Drug Interactions Group, University of Liverpool Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF
We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions



Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to co-administer.
BOC, Boceprevir; DCV, Daclatasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Omibitasvir/Paritaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; TVR, Telaprevir; Peg IFN, PEGylated Interferon; RBV, Ribavirin.
Cells have been left blank for the unassessed interactions with PEG-IFN or RBV.

Key to symbols

Filled symbols indicate further information is available at www.hep-druginteractions.org.

Empty symbols indicate the interaction has not been assessed (either by study or within the product label) and has been predicted based on the metabolic profiles of the drugs.

	These drugs should not be coadministered
	Potential interaction – may require close monitoring, alteration of drug dosage or timing of administration
	No clinically significant interaction expected

Notes

- Predicted interactions are based on known metabolic pathways. Interaction studies performed with boceprevir and telaprevir have shown some inconsistencies which suggest unknown mechanisms may contribute to drug-drug interactions and therefore predictions may not always reflect the clinical situation.
 - Caution is required in patients with hepatic impairment as this may also increase drug levels.
 - Where advice differs between countries, the charts reflect the more cautious option.
 - Further comedications will be added when information is available.

© Liverpool Drug Interactions Group,
University of Liverpool

Pharmacology Research Labs, 1st Floor Block H,
70 Pembroke Place, LIVERPOOL, L69 3GF

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise, howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.